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Objective: To evaluate the outcomes of ART in women age of 40 years and above 
Design: Retrospective descriptive study 
Setting: Tygerberg Academic Hospital, Reproductive Medicine Unit 
Population: All women aged 40 years and above who had undergone ART 
for infertility at the Tygerberg Reproductive Medicine Unit  
Methods: Medical records of all patients who qualify to be included in the study were 
reviewed and information regarding indications, treatment offered and outcomes were 
retrieved and logged in proforma data spreadsheet.  
Main outcome measures:  
The primary outcome measures are the LBR, OPR & CPR.  
Secondary outcome measures are number of oocytes retrieved, fertilization rates, 
quality of embryos, cycle cancellation rates, miscarriage rates and complication rates 
(multiple gestations or ovarian hyperstimulation rates [OHSS]). 
Results: Ovulation induction was performed on 268 women (n=268) after excluding 2 
women who had used oocyte donation. The biochemical pregnancy rate was 8,2% as 22 
women had a positive βhCG test on day 10. Of these, 9 had a foetal heart rate on 
ultrasound yielding a clinical pregnancy rate (CPR) of 3,3%. 3 pregnancies reached term 
with 2 being documented as having given birth and 1 lost to follow up hence the live birth 
rate was only 0,7% (2/268) per cycle and a miscarriage rate of 66,7%. 
Conclusion: Reproductive outcomes in older women undergoing ART have a low 
success rate as evidenced by the low live birth rate of 0,7% and miscarriage rate of 66%. 
It is therefore essential that older women are thoroughly informed about expected 
outcomes prior to them embarking on their ART journey 
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 Biochemical pregnancy is defined as a pregnancy diagnosed only by detection of 
βhCG in serum or urine  
 Clinical pregnancy is defined as a presence of a foetal heart on ultrasound at 
seven weeks of gestation 
 Ongoing pregnancy rate is defined as the presence of a foetal heart rate on 
ultrasound at twelve weeks of gestation. 
 Livebirth is defined as the complete expulsion or extraction from its mother of a 
product of fertilization, irrespective of the duration of the pregnancy, which after 
such separation, breathes or shows other evidence of life such as heartbeat, 
umbilical cord pulsation or definite movement of voluntary muscles irrespective of 
whether the umbilical cord has been cut or the placenta is attached. 
 Infertility is the inability to conceive after 12 months of adequate (regular & 
unprotected) sexual exposure 
 Primary infertility is when a pregnancy has never been achieved  
 Secondary infertility is when at least one prior pregnancy has been achieved 
 Fecundity is the probability that a cycle will result in a live birth 
 Fecundability is the probability that a cycle will result in pregnancy 
 Foetal viability is reached at 27 weeks of gestation and an estimated foetal weight 




CHAPTER 1: INTRODUCTION 
 
1.1 INFERTILITY IN AN AFRICAN CONTEXT 
Childbearing and rearing are important events in the life of every human being and are 
possibly associated with the ultimate goal of completeness, happiness and family 
integration [1]. In Africa motherhood is used as measure of a woman’s reputation in 
society, a source of power, pride, an important aspect of life and cultural expectation 
within a marriage [2]. Hence the inability to conceive is a major problem that is 
stigmatising to many people and this often leads to delay in seeking treatment out of the 
fear of being labelled as “infertile” [3]. Women delay childbirth due to societal changes, 
cultural expectations and financial situations which leads to more women seeking 
treatment for infertility in their late reproductive years [4]. The challenges of older women 
seeking fertility treatment include poor outcomes, increased risk of miscarriages and 
pregnancy related complications. [4] Additional challenges in Sub Saharan Africa include 
limited access to assisted reproductive technology (ART) clinics, affordability, geographic 
barriers and lack of infrastructure required for ART [5]. 
 
1.2 EPIDEMIOLOGY OF INFERTILITY 
Infertility is defined as the inability to conceive after 12 months of regular unprotected 
sexual intercourse. It is estimated to affect as many as 186 million people worldwide, 
which is 8-12% of reproductive aged couples [6]. The population that is affected by 
infertility is higher in low-income countries in comparison to high-income countries. The 
rate of infertility is reported to be as high 30% in some regions including Sub Saharan 
Africa [6]. Primary infertility is more prevalent in young women of reproductive age (20-
29 years) in comparison to their older counterparts (30-44 years) [2]. The prevalence of 
secondary infertility increases sharply with age from 2,6% in women aged 20-24 years to 
27,1% in women aged 40-44 years [7]. Secondary infertility is the second most common 
form of female infertility around the globe with unexplained infertility being the commonest 
cause in women over 35 years [6,8]. Fecundity progressively declines in older women 
due to a decline in ovarian function in this age group, while fecundability decreases with 
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an increase in both maternal and paternal age [9]. 
 
1.3 CAUSES OF INFERTILITY 
The major causes of infertility include tubal and pelvic pathology (30-40%), ovulatory 
dysfunction (20-40%), male factors (30-40), uterine pathology is relatively uncommon, 
and the remainder is largely unexplained [8]. The prevalence of each cause varies with 
age, with ovulatory dysfunction being more common in younger than older couples and 
tubal and pelvic factors have a similar prevalence [8]. Male factors and unexplained 
infertility are observed often in older couples [8]. The most common factors associated 
with infertility as women age are secondary amenorrhea, polycystic ovary syndrome 
(PCOS), uterine myomas and endometriosis [9]. Infertility is high (25%) amongst women 
with PCOS and becomes more severe with age [9]. Myomas are known to increase in 
size and number during the fourth decade thereby reducing fertility with their effects on 
the endometrial cavity, altering uterine contractility and reducing endometrial receptivity 
[9]. The incidence of cancer during pregnancy is expected to rise with concomitant 
increasing age of childbearing [10]. In low and middle income countries (LMIC) genital 
tract infections and sexually transmitted diseases are important risk factors for tubal 
disease & male factor infertility [9]. Endometriosis impairs fertility via multiple mechanisms 
which include distortion of pelvic anatomy through the formation of adhesions, altered 
peritoneal function that has an adverse effect on fallopian tube function and altered 
hormonal and cell mediated function which may alter endometrial receptivity [11]. 
Nulliparity is a risk factor for endometriosis and its prevalence is highest during the third 
and fourth decade of life, when the modern women who has delayed childbearing often 
wishes to conceive [9]. Lifestyle factors such as smoking, abnormal body weight 
(BMI<19kg/m² and >25kg/m²), alcohol and coffee consumption, psychological and 
physical stress as well as environmental pollutants such as radiation have an adverse 
effect on fertility [9]. The probability of conception depends on oocyte quality, which is 
determined by the women’s age; according to the American College of Obstetrics and 
Gynecology (ACOG) the fecundity of a women decreases gradually but significantly 





Figure 1: Relationship between maternal age and natural fertility (rate of pregnancy/1000 
women) as adapted from SOGG Clinical Practice Guidelines Nov 2011 [12,20]. 
 
 
Figure 2: Schematic representation of the number of primordial follicles present in the 
ovaries and the chromosomal quality of oocytes in relation to female age and 





1.4 AGE RELATED INFERTILITY 
There is a natural age-related decline in fertility that is observed even in populations that 
do not use contraception [12]. This is often accompanied by a decrease in oocyte quality, 
which can be attributed to a complex series of age-related changes in nuclear and 
cytoplasmic competence. These changes usually affect crucial processes such as spindle 
formation, mitochondrial function and cytoskeletal integrity resulting in abnormal 
chromosome segregation [13]. This may lead to the production of poor quality oocytes 
that are less likely to fertilise; and if fertilised the embryos may be slow to divide and 
unlikely to implant [13]. Societal factors have led to a rise in the incidence of women who 
delay childbearing well into their late reproductive years [14]. This in turn may lead to 
increased numbers of women seeking assisted reproductive technologies (ART) [15]. 
Women now focus on getting educated and pursuing careers which leads to an increased 
age at first marriage and hence delayed childbearing [14]. The driving force behind the 
shifting paradigm in modern reproductive forces is estimated to have begun in the 1960’s 
with the advent and use of safe, effective, affordable and accessible oral contraceptive 
pills; providing women with the opportunity to control their own reproductive destinies [16]. 
Health education offered to adolescents tends to focus on the precautions of pregnancy 
prevention i.e., during contraceptive counselling, the dangers of delayed childbearing are 
not discussed [16]. Legalization and social acceptance of abortion in many countries has 
also left little room for error after failed contraception [17,18]. This decreases the chances 
of earlier unplanned pregnancies with childbearing being delayed until financial stability 
is achieved. The rise in the divorce rate has also led to a rise in second marriages at a 
later stage and a need to start a family with the new partners [8]. There is also a 
misconception that childbearing can be delayed until the later years of life with the hope 
that ART can compensate for age related infertility [17]. 
 
Older women are at increased risk of early pregnancy, obstetric and neonatal 
complications, with this risk being pronounced in women over 35 years of age [13,18]. 





In the general population the risk of miscarriage in women 35-39 years of age is 24% and 
doubles to 51% at 40-44 years of age if the women conceive on their own without the use 
of donor eggs [12]. A wide variety of obstetric complications are associated with advanced 
maternal age, these include higher chances of operative delivery, aneuploidy, caesarean 
section, hypertensive disorders, peri-partum cardiopathy, placenta praevia, abruptio 
placenta, diabetes (gestational and pregestational), multiple pregnancies, intra-uterine 
growth restriction (IUGR) and low birth weight [13,18]. Use of ART is associated with an 
increased incidence of multiple pregnancies at all ages, and this further increases the risk 
profile for obstetric complications [19]. Older women are more likely to have pre-existing 
medical disorders such as chronic hypertension and diabetes of which some may be 
exacerbated by pregnancy. There has been inconclusive data about the effects of 
infertility treatments (especially hormonal methods) on cancer development; 
nevertheless, older women who undergo ART should be counselled on the possible 
associations [10].  
 
1.5 TREATMENT OPTIONS FOR AGE RELATED INFERTILITY 
Treatment options for older women with infertility include ovulation induction & timed 
intercourse, ART (in-vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI) with 
usage of own eggs or donor eggs, adoption or childless living [20]. Proposed strategies 
to improve treatment outcomes in older women seeking assistance include modified 
ovarian stimulation protocols, assisted hatching of embryos and addition of androgens to 
improve oocyte quality [21]. But none of these have shown any significant improvement 
in the results. The most effective strategy is oocyte donation especially in women with 
reduced ovarian reserve [22,24]. Embryo and oocyte cryopreservation are possible 
options and should be considered by women who plan to delay childbearing [24]. In 2012 
the American Society for Reproductive Medicine (ASRM) also declared that egg freezing 
should not be considered experimental and in some literature it is considered to be 
preventative medicine for age related fertility decline [25].  
 
The ideal age for egg freezing is 30-35 years, from the age of 38 years there is low 
probability of successful thawing, fertilisation, implantation and live birth [25]. It is cost 
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effective to freeze oocytes at an age below 35 years. Freezing at 38 years & above is not 
cost effective and should not be recommended. The latter implies that there is a mismatch 
between patient demand and optimal outcome as the likelihood of poor outcomes is high 
in women aged over 40 years [25]. However, gamete donation or third party reproduction 
(such as surrogacy and adoption) is not always well received as it does not provide a 
genetic link between mother and child [23]. Third party reproduction may also pose a 
dilemma from a religious point of view as different religious vocations have different views; 
Islamic religious laws view it as adultery whereas Judaism in Israel is so receptive that it 
is the only country that offers government subsidy for gestational surrogacy [26]. The 
Catholic Church has clearly prohibited ART use, but nations influenced by Catholism have 
varied responses; Hinduism on the other side has not specifically addressed ART and 
seems to be permissible as ART accords with several characteristics of the Hindu 
thoughts [27]. Therefore most women will opt to attempt treatment using their own oocytes 
despite the risk of poor outcomes. This has led to the motivation to evaluate ART 
outcomes of older women (≥ 40 years) receiving treatment at Tygerberg Academic 





CHAPTER 2: RATIONALE FOR STUDY AND METHODOLOGY 
2.1 RATIONALE FOR STUDY 
Due to lack of guidance regarding the care of older women seeking fertility treatment in 
limited resource settings, this information will improve the ability of clinicians to counsel 
their patients regarding treatment outcomes. The study will also form the basis for future 
research into alternative strategies. 
 
2.2 AIM 
To evaluate ART outcomes in older women at Tygerberg Academic Hospital, 
Reproductive Medicine Unit.  
 
PRIMARY OBJECTIVE 
To investigate livebirth rates (LBR) and if not available, the ongoing pregnancy rates 
(OPR) and if not available, clinical pregnancy rates (CPR) of older women (≥ 40 years) 




- The number of oocytes retrieved 
- Fertilization rates 
- Embryo quality 
- Cycle cancelation rates 
- Miscarriage rates 




Study design: Retrospective descriptive study 
Study population: All women seeking assisted reproductive technology in the form of 
IVF and ICSI 
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Setting: Tygerberg Reproductive Medicine Unit between 2016-2018 
Inclusion criteria: All women 40 years and older who received ART using their own 
oocytes at Tygerberg Hospital 
Exclusion criteria: All oocyte donation cycles were excluded as well as women younger 
than 40 years of age. 
Data collection: 
Data was obtained from patient records a using proforma data collection sheet presented 
as (Appendix 3). Data was collected using patient’s folder numbers only, no names or 
identifiable information was used. All data was coded to protect the identity of the patients 
and was entered into an appropriate spread sheet for analysis 
Data management & analysis: 
Sample size calculation was discussed with a statistician. Data from the data collection 
tool was entered into a spreadsheet and analysed using the latest version of STATISTICA 
in consultation with a biostatistician from the Biostatistics unit. Continuous data was 
analysed descriptively using means and standard deviations if data is uniformly 
distributed, and medians and interquartile ranges if data is not uniformly distributed. The 
95% confidence interval was calculated. Nominal data was presented using absolute and 
relative frequencies with 95% confidence interval being used for binomial proportions. For 
the primary outcome, an analysis of variance (ANOVA) was performed. For comparing 
two continuous or ordinal variables, Pearson correlations was used if data are normally 
distributed and the Spearman rank order correlation if data are non-normally distributed. 
For comparing a single binary variable with a continuous variable, a T-test was used if 
data are normally distributed and a Mann-Whitney U test if data are non-uniformly 
distributed or if heterogeneity of variance exists.  
 
For comparing a single nominal variable with a continuous variable an appropriate 
ANOVA was used. If the nominal variable represents dependent groups or measurements 
over time the repeated measures ANOVA was performed or a Friedman’s test if data is 
ordinal. The relation between two nominal variables was investigated with contingency 




Implementation of findings: 
The result will be presented at relevant scientific meetings and the Academic Year Day of 
the Stellenbosch University. A manuscript will be prepared and submitted for publication 
in a national or international journal as an original research article. 
Ethical consideration: 
Ethics approval was obtained from the Health Research Ethics Committee of the Faculty 
of Medicine and Health Sciences, Stellenbosch University (Study no:1514), prior to 
commencement of the study. Ethics approval is presented in (Appendix 1) 
Informed consent: 
This is a minimal risk study because it is a retrospective review of patients’ medical 
records and application for waiver of informed consent was submitted and approved 
(Appendix 2) 
Confidentiality: 
All patients were assigned an individual study number that was not linked to their names 
or hospital numbers to protect their identities and to maintain confidentiality. Identity of 
the patients was only known to the principal investigator who was keeping the details of 
the information in a secure office and only accessed the information for verification 
purposes. The computer used for coding and storing patients informational is password 
protected. 
Study timelines: 
The study was envisaged to take period of approximately 6-9 months following approval 
from the Health Research Ethics Committee of the Faculty of Medicine and Health 
Sciences, Stellenbosch University. 
Study Limitations: 
Incomplete or missing clinical information and illegible hand writings are potential 
limitations to the study. 
Study team: 
The study team comprises the Principal investigator, Supervisor, Statistician allocated 






On receipt of approval from the Health Research Ethics Committee data was collected 
from patients using structured questionnaires. Data was extracted, coded and entered 
into a spreadsheet. With the assistance of the Statistician data was analysed and 
interpreted. Findings were compared to available published literature and reported 
accordingly. 
Budget: 
Expected costs: stationery R1500. 
The study was self-funded. 
Tygerberg Reproductive Medicine Unit Protocol and Standard Operating Procedure 
(SOP): 
 Ovarian stimulation protocols 
 Standard ovarian stimulation protocol according to SOP of the Tygerberg Hospital 
Fertility Clinic were used. Ovarian stimulation occurred with the administration of 
medication that stimulated the ovaries to produce multiple oocytes via follicular 
development 
 Oocyte retrieval  
 A standard oocyte retrieval procedure according to the SOP of the Tygerberg Hospital 
Fertility Clinic has been used. Briefly, follicular fluid was aspirated, using an ultrasound 
guided method and examined for the presence of oocyte-corona complexes (OCC). 
Subsequently the oocytes were graded germinal vesicles (GV), metaphase one (MI) and 
metaphase two (MII) and finally transferred to fertilization medium 
 Semen preparation 
Semen was processed using standard, routine protocols. Both the Swim up and Gradient 
centrifugation preparation methods were done depending on the semen characteristics 
 
 Fertilisation/insemination process 
Mature MII oocytes were fertilized using standard protocols of IVF and ICSI 
 Embryo culture 
 Standard embryo culture methods were used. Oocytes were cultured in either sequential 
(fertilization, cleavage and blastocysts) or 1 Step medium (Sage®, Harrilabs) in a CO2 
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incubator at 37ºC for up to 5 days. 
 Embryo evaluation- specifically Day 3 embryos 
Standard day 3 embryo evaluation for quality and morphology was followed. Embryos 
were graded according to the number of cells present and quality thereof using a 
modified Veeck et al classification (Veeck, 1999). Good quality embryos include the 
following: 
Table 1: Veeck classification for embryo grading 
 
All good quality embryos that were not transferred were cultured and vitrified using 
standard protocols 
 Follow up and pregnancy assessment 
On all patients a day 10 βhCG test was done to establish the biochemical pregnancy rate. 
An ultrasound was performed around 12 weeks to confirm presence or absence of a foetal 





CHAPTER 3: RESULTS 
3.1 DEMOGRAPHIC DATA 
There were 268 patients included in the study after excluding 3 patients who were 40 
years and above but had used donor oocytes. The study population comprised of women 
ranging from 40-45 years of age with a mean age of 41yrs. Data was collected from the 
Tygerberg Reproductive Medicine Unit (treatment period 2016-2018). Unexplained 
infertility (39,8%) was the most common female diagnosis, followed by tubal factor 
infertility (30,9%) & uterine factors (16,3%) [Table 2]. 
 
Table 2: Demographic data 
Demographic data Numbers (n) % of patients 
Primary 130 48,5 
Secondary 80 29,8 
Unknown 58 21,6 
Female diagnosis   
Idiopathic 107 39,8 
Tubal factor 83 30,9 
Endometriosis 34 12,6 
Myoma 10 3,7 
PCOS/POI 4 1,5 
Male factor 7 2,6 
Ovarian reserve/low AMH 6 2,2 
Other 17 6,3 
Male diagnosis   
Normozoospermia 94 35 
Teratozoospermia 36 13,4 
Testis biopsy 30 11,2 
Donor sperm 25 9,3 
Oligo teratozoospermia 8 2,9 
Oligo astheno teratozoospermia 6 2,2 
Oligozoospermia 6 2,2 





3.2 TREATMENT VARIABLES 
Two different ovulation induction protocols were used on 268 patients, of which 87% 
received clomiphene and Menopure® (mild ovulation stimulation protocol) and 12,6% 
received conventional IVF stimulation protocol with GnRH antagonists [Table 3]. 
 
Table 3: Treatment variables 
Stimulation protocol Number (n) % of Patients 
Clomiphene or HMG/FSH 234 87 
HMG & GnRH antagonists 34 12,6 
Procedures   
ICSI 87 62,6 
IVF 39 28,1 
Cancelled cycles: 
 Poor follicular growth 
 No of oocytes during retrieval 












FET 4 2,9 
Cycle number   
1 cycle 136 50,7 
2 cycles  61 22,7 
3 cycles  27 10 
4 cycles & greater 17 6,3 
Unknown 27 10 
Donor sperm   
No 189 72,7 





3.3 TREATMENT OUTCOMES 
Three to nine oocytes were retrieved in 52,4% of patients, with two or less being retrieved 
in 43,5% while a minority of patients 0,8% had more than nine oocytes. The overall cycle 
cancelation rate was 31%. The majority of embryos, 82,6% were transferred between day 
three-five, with only 1,6 % being transferred on day six and 15,7% were transferred 
between day one-two [Table 4]. 
 
Twenty-two women had a positive βhCG test on day ten resulting in a biochemical 
pregnancy rate of 8,2% (22 out of 268). The clinical pregnancy rate was 3,3% as 9 women 
had a positive pregnancy test as demonstrated by a positive fetal heart on ultrasound with 
a miscarriage rate was 66,7% as only 3 reached term. Three pregnancies reached term, 
however only two were recorded to have given birth with one being lost to follow up. 




Table 4: Treatment Outcomes 
Treatment outcome Number (n) % of Patients 
Biochemical Pregnancy rate 22 8,2 
Clinical/Ongoing Pregnancy rate  9 3,3 
Livebirth rates  2 0.7 
Miscarriage rate  6 66 
Term pregnancies  3 1,1 
   
Number of oocytes retrieved/aspirated:   0   25  9,3 
1-3 145 53,9 
4-7   84 31,6 
>7    6   4,9 
Endometrial lining:   <8mm   23 10,9 
8-12mm 178 84,7 
>12mm   17   2,3 
Fertilisation rates 629/736 
x 100 
85.4 
Embryo quality:   
GQE 318 82,3 
PQE   68 17,6 
Number of embryos transferred:   
No transfer 57 23,6 
One 60 24,9 
Two 58 24,1 
Three 54 22,4 
Four 12 5 
   
Day of embryo transfer:   
Day 1 1 0,5 
Day 2 28 15,2 
Day 3 107 58,2 
Day 4 19 10,3 
Day 5 26 14,1 




CHAPTER 4: DISCUSSION  
The biochemical pregnancy rate was 8,2% (22 out of 268) as measured with βhCG on 
day 10, with a clinical/ ongoing pregnancy rate of 3,3% (of the 22 women who had a 
positive βhCG on day ten, 9 had a positive foetal heart on ultrasound at seven and twelve 
weeks). Of the 9 pregnancies, 3 progressed to full term resulting in a miscarriage rate 
(MR) of 66% (6 out of 9) Table 4. In this study we confirmed 2 live births which results in 
a LBR of 0,7% per treatment cycle started. These findings are comparable to results 
reported by Aflootian et al 2011 in a retrospective study done in Iraq. They evaluated 
pregnancy outcomes of 313 women aged 40 years and above, undergoing ART. They 
found, biochemical pregnancy rate of 8,6%, CPR of 3,8%, MR of 63%, cancelled cycles 
of 23,3% and a LBR of 3,3% [28]. Aflootian et al define a live birth as the birth of at least 
one live born after 20 weeks, which in our setting would be defined as a miscarriage. 
Their findings and our study findings showed that the ART outcomes are generally poor 
in older women. However, a retrospective analysis by Auge et al, that involved 1939 who 
were 40 years and beyond using autologous oocytes reported LBR of 12,3% which is 
much higher than our study findings [29]. The higher LBR could be attributed to a larger 
sample size & a study population from a high resource setting, together with advanced 
neonatal facilities and therefore define foetal viability from 24 weeks gestation. The poor 
outcomes in terms of poor pregnancy rates, high miscarriage rates and cancellation rates 
reflect the poor oocyte quality in this context. 
 
In this study we found high rates of cycle cancellation (31%) due to poor follicular growth 
(9,7%) no oocytes at the time of aspiration (8,2%) and poor embryo development (12,7%) 
among other reasons. These findings are similar to those reported by other authors 
[28,33,34]. The literature demonstrates that advanced maternal age seems to have an 
unfavourable impact on many aspects of ART such as cancellation rate, as most studies 
have a cancellation rate around 22-24% [28,29,33,34]. Aflootian et al & Auge et al found 





Oocyte aging which could lead to low fertilisation rates and poor quality embryos as well 
as oocyte depletion are known phenomenon with increasing maternal age (Figure 1 and 
2). Hence these findings are typical in this age group of patients as demonstrated by the 
similarity of the cancellation rate despite vast differences in sample size and clinical 
setting. Rate of pregnancy loss is elevated in older women due to the association of 
aneuploidy with oocyte aging. The miscarriage rate was 66% which was comparable to 
that found by Aflootian et al of 63% but Auge et al had a much lower miscarriage rate of 
33% [28,29]. In a retrospective analysis by Klipstein et al the miscarriage was significantly 
lower at 32,6%, a finding that pregnancy loss was lower if good quality multiple embryos 
were transferred and two foetal hearts were visualised [32]. To avoid raising false hope 
such findings should be interpreted with caution and discussed during counselling before 
embarking on ART with older women. 
 
The highest number of oocytes found during aspiration in this study is 13 oocytes (0,4%). 
About 34,2% of patients showed poor response to ovarian stimulation (<3 oocytes), with 
52,4% showing an optimal response(3-9 oocytes) & 0,8% showing an excessive 
response (>9 oocytes) [Table 4] with a mean of 5,5 oocytes retrieved, while Aflootian et 
al found a mean oocyte retrieval of 3,2. Steven et al had about 30% of patients with 
cancelled cycles due to poor response with mean number of oocytes retrieved of 6,8 [33]. 
These findings go to show that the number of oocytes is not a good predictor of ART 
success in older women, possibly in younger women as well. The mean number of 
fertilised zygotes in this study was 4,5 which is comparable by that found by Steven et al 
of 5,4 [33]. Supernumerary oocytes do not confer a cumulative live birth rate benefit to 
patients predicted to be high responders, moreover they may contribute to an increase in 
observed adverse effects such as ovarian hyper stimulation syndrome. Retrieval of high 
numbers of oocytes (>15) had a negative impact on the ongoing pregnancy rate in fresh 





A retrospective cohort of 737 infertile women undergoing their initial fresh embryo non 
donor IVF or ICSI was done to evaluate the association between the number of mature 
oocytes per assisted reproductive technology cycle and the likelihood of a live birth. The 
study concluded that the minimum mature (phase II metaphase) oocyte yield that predicts 
a live birth after ART is six (6) meaning, retrieving more than six mature oocytes did not 
translate into a better chance for a take-home baby and conversely in cycles with five or 
fewer mature oocytes there was significantly lower likelihood of live birth [41]. That will 
mean the average 35 year old patient needs on average 5 oocytes to expect a euploid 
embryo while, patients over 42 years need 20 oocytes [44]. Embryo development is a 
good indicator of oocyte quality. In this study we found 318 (82,3%) good quality embryo 
and 63 (17,6%) poor quality embryo. The number of embryos transferred and the day of 
transfer did not seem to influence the outcomes in this study (Table 4). However, some 
studies suggest multiple embryo transfer and early transfer on day 2/3 is associated with 
better pregnancy outcomes [48]. Combelles et al suggested that in women > 40years, 
five embryos are the optimum number to transfer and transferring more than five embryos 
does not confer any additional benefit to clinical outcome [44]. There were no cases of 
multiple pregnancies and ovarian hyperstimulation reported in this study. These findings 
were reassuring as these complications should be minimised at all times especially in 
older women with co-morbidities and in resource restricted settings. 
 
Current adjuvant treatments available have limited success in improving oocyte quality 
and ability to generate genetically competent embryos, making donor oocyte an option 
rather than solely a treatment for IVF failure [42]. Such treatments include adjuvant use 
of DHEA or testosterone to increase ovarian responsiveness to stimulation, human 
growth hormone or antioxidants like CoQ10 to potentially improve egg and embryo 






More favorable pregnancy and implantation rates obtained by patients could depend on 
the pattern of GnRH antagonist administered [38]. The latter statement was a conclusion 
of a study done on poor responders and women aged > 35 years randomized into group 
1 (received standard long GnRH protocol) and group 2 (received recombinant human 
FSH and clomiphene citrate and when at least one follicle of 16mm in diameter was 
observed a GnRH antagonist was administered in a multi dose fashion until follicles were 
greater than or equal to 18mm). It was concluded that the latter protocol (group 2) could 
be usefully administered in poor responders and aged women to obtain lower cancellation 
rates, greater oocyte recovery and more favourable pregnancy and implantation rates 
[38]. 
 
In patients aged 40 years and over, there is a reduced ovarian reserve, with a lower 
number of oocytes remaining in the ovary which may lead to markedly lower expectancy 
of pregnancy rates per cycle in comparison to younger women [39]. A controlled 
randomised study was done on two hundred and twenty women who were 40 years and 
older undergoing IVF (ICSI) that aimed to determine the efficacy of the short versus the 
long GnRH analogue suppression protocols. The findings were that the long protocol 
performed better than the short protocol in older women as it resulted in higher numbers 
of oocytes harvested, higher numbers of embryos obtained, higher implantation rates and 
higher pregnancy rates [39]. A randomised control trial compared three different protocols 
of ovarian stimulation in 250 poor responder women; clomiphene citrate, high dose of 
gonadotrophins and antagonist (68) versus flexible GnRH antagonist (71) versus short 
GnRH agonist protocol (75). The study demonstrated that short GnRH agonist should be 
first choice in poor responders and clomiphene citrate should be avoided due to it’s very 
low success rate. [40] For controlled ovulation induction 233 patients in the index study 
received clomiphene citrate and human menopausal gonadotrophin (HMG) whereas 34 
received HMG and gonadotrophin releasing hormone with 1 patient receiving an 
aromatase inhibitor. Klipstein et al used one of three protocols (GnRH analogues +/- 
pretreatment oral contraceptives/an antagonist protocol/HMG +/- recombinant FSH) that 
were individualised according to patient factors with human chorionic gonadotrophin 
(hCG) administered in patients with 2-3 follicles greater than/equal to 14mm and the mean 
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number of embryo transferred was 3,1.  
 
The outcomes were much better with a LBR that was nine times higher than that found in 
the index study with a lower miscarriage rate (44% vs 66%). Klipstein & Auge et al did not 
use clomiphene whereas in our study the majority of patients received a protocol 
containing clomiphene citrate which seems to be associated with poor outcomes in 
comparison to protocols containing gonadotrophin analogues. 
 
In light of the poor pregnancy outcomes, it is advisable that couples should receive 
counselling regarding poor conception rates, high miscarriage rates etc. Alternative 
methods such as oocyte donation, surrogacy and adoption should be discussed. Oocyte 
donation makes up an increasingly large percentage of all ART cycles worldwide [30]. 
However, it presents a challenge for the clinician who not only has to serve interests of 
both the donor and the recipient but has to deal with a complex situation which includes 
synchronising both donor and recipient cycles. It is associated with stable implantation, 
clinical pregnancy and delivery rates among recipients aged 25 to mid- 40’s [30]. Donor 
pregnancy rates are generally as high as 48,1% and 28,5% with use of fresh and 
cryopreserved oocytes respectively in the age range 40-44 years but began to decline 
from mid 40’s to 44% and 26,65% [31]. The latter are findings of a retrospective cohort 
study of aggregated national cycles of donor egg therapy collected by the Society of 
Assisted reproductive Technology (SART) and the Centers for Disease Control and 
Prevention (CDC) [31]. A retrospective cohort study by Yeh et al showed a decline in 
success rates in older recipients; with an implantation rate of 40,9%, a clinical pregnancy 
rate of 59,9%, a live birth rate of 48,6% and a miscarriage rate of 19% in recipients who 
were 50 years and older [48]. 
 
For some couples oocyte donation/adoption may not be an acceptable option for various 
reasons including fear of not having a genetic link with the offspring, cultural, or religion. 
In a Japanese survey about public attitudes towards third party reproduction, 40% of 
responders found third party reproduction socially unacceptable because the parent child 
relationship will be unnatural [51]. 
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More women are delaying childbearing due to societal changes, and advances in ART 
have made conception possible for women of advanced age [28]. However, advanced 
maternal age is associated with medical and obstetric complications and can present an 
ethical dilemma to clinicians. Recognizing the poor treatment outcomes based on our 
study findings (LBR =0,7%) and other literature reports, and taking into consideration the 
high costs of ART services; the question is, should we be offering ART services for women 
40 years and older with autologous oocytes? This is an ethical and moral question that 
needs to be constructed in reproductive medicine conversations and debate. Therefore, 
the conversations around the age-related decline in fertility and social oocyte 
cryopreservation should possibly be stimulated hand in hand with reproductive health 
(including contraception) counselling in women of childbearing age.  
 
4.2 STRENGTHS AND LIMITATIONS: 
In our knowledge this study is the first to assess outcomes of ART in women 40 years 
and older in a low resource setting. This study will hopefully stimulate more research 
ideas in the field of ART in older women, in investigating factors that may improve 
outcomes. The limitations of this study are, data was collected from patient records which 
limits information details and increases the risk of missing data. It is also a retrospective 
analysis and that offers an inferior level of evidence in comparison to prospective studies 
or randomised controlled trials. Other confounding variables such as co morbidities that 
could affect female fertility hence affect the outcomes of ART were not addressed. The 





CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
 
CONCLUSION: 
Reproductive outcomes of ART of women 40 years & older are associated with a low 
success rate of 0,7% LBR and 3,3% CPR/OPR in this study. This study also reported high 
rates of miscarriage (66%). Oocyte aging and poor oocyte quality as illustrated by high 
cycle cancellation rates (31%), low number of oocytes collected during aspiration and 
poor embryo development seems to be the main reason for poor outcomes in this study. 
There were no cases of HOMP, which was reassuring. We do believe that infertility and 
contraception should be communicated under one platform in sexual and reproductive 
health and to raise public awareness about age-related fertility decline. This will allow 
women who wish to delay childbearing due to personal, health or social reasons to 
explore options such as egg freezing earlier in life rather than later. 
 
FUTURE STUDY RECOMMENDATIONS: 
The study findings stimulate debate around ART service provision for older women in 
limited resource settings. It also highlights the need for more studies that will be required 
to address issues related to the type of patient profile and other markers that could identify 
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APPENDIX 2       27 Nassau Street 
                Parrow 
                Cape Town 7505 
                19 December 2018 
 
To: The Health Research Ethics Committee 
      University of Stellenbosch 
 
RE:APPLICATION FOR CONSENT WAIVER 
  
I, Dr N S Nkangana will be conducting a retrospective descriptive study on the outcomes 
of assisted reproductive technologies in older women (40yrs & above); and would therefore 
like to apply for waiver of consent.  
 
The lab personnel, my supervisor & I will have access to the medical records. Data will be 
collected using hospital medical records that are locked in the reproductive medicine 
department laboratory. The research will pose no risk to the participants nor will it affect 
their rights & welfare. There will be minimal risk of invasion of patient’s privacy as data 
will be collected using folder numbers, no identifiable information will be used & the data 
will be coded to protect the patients’ identities. 
 
I hope my request will receive your favourable consideration 
 
Yours faithfully  
 
N S Nkangana  
Medical Registrar 
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